A Phase 4 interventional study of brimonidine tartrate/timolol malate Ophthalmic Solution and bimatoprost ophthalmic solution 0.01% in Glaucoma, Open-Angle and Normal Tension Glaucoma, sponsored by Allergan. Completed at 9 sites in Korea, Republic of. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-31.
Sponsored by Allergan (part of AbbVie) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies in Glaucoma, Open-Angle by AbbVie — 1 open to participants now, 3 under way, 1 of them phase 3. Glaucoma, Open-Angle · AbbVie.
Among the 58 studies in Glaucoma, Open-Angle by AbbVie, this one is the 24th largest by enrollment of the 34 interventional ones that give a count, is the only one that started in 2016, is one of 14 in phase 4, and was the 49th registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
Browse Glaucoma, Open-Angle studies →1 of the 58 studies in Glaucoma, Open-Angle by AbbVie is open now, in 1 country. Recruiting first, the newest first:
AbbVie · Sites in United States
Ages 45+
By country, each count listing its studies:
Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 12 · Phase 4 14
First in 1999; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 118 is above the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Median enrollment 164 across the 34 interventional studies, 419 across the 23 observational. Of the 54 that completed or were terminated, 42 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 58 studies in Glaucoma, Open-Angle by AbbVie, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to evaluate the long-term efficacy and safety of COMBIGAN® (brimonidine tartrate/timolol malate) in patients only using COMBIGAN® (brimonidine tartrate/timolol malate) and also in patients who require additional IOP lowering with LUMIGAN® (bimatoprost) 0.01%.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
One drop of COMBIGAN® in the affected eye, administered twice daily for 12 months
Drug: brimonidine tartrate/timolol malate Ophthalmic Solution
LUMIGAN® will be administered once daily in the evening 5 minutes after COMBIGAN® instillation in patients who require additional IOP lowering.
Drug: brimonidine tartrate/timolol malate Ophthalmic Solution · Drug: bimatoprost ophthalmic solution 0.01%
One drop of brimonidine tartrate/timolol malate (COMBIGAN®) Ophthalmic Solution in the affected eye, administered twice daily for 12 months
Bimatoprost ophthalmic solution 0.01% (LUMIGAN®) administered once daily in the evening 5 minutes after COMBIGAN® instillation if additional lowering IOP is needed
Mean IOP change from Baseline (11AM point)
Time frame: Baseline, Month 12
Mean IOP change from Baseline (11AM point)
Mean IOP change from baseline (11AM point) in the following patient sub-groups 1. patients with NTG 2. patients with POAG 3. patients taking Combigan alone 4. patients taking Combigan plus additional Lumigan 0.01%
Time frame: Baseline, Month 12
Mean IOP change from Baseline (9AM point)
Mean IOP change from baseline (9AM point) in the following patient sub-groups 1. patients with NTG 2. patients with POAG 3. patients taking Combigan alone 4. patients taking Combigan plus additional Lumigan 0.01%
Time frame: Baseline, Month 12
Mean change in Mean deviation (MD) from Baseline
Time frame: Baseline, Month 12
Mean change in Pattern standard deviation (PSD) from Baseline
Time frame: Baseline, Month 12
Mean change in Visual field index (VFI) from Baseline
Time frame: Baseline, Month 12
Mean change in cup to disc ratio (C/D ratio) from Baseline
Time frame: Baseline, Month 12
Rate of VF progression measured as change in VF index over time
Rate of VF progression during 12 months in the following patient sub-groups. 1. patients with NTG 2. patients with POAG 3. patients taking Combigan alone 4. patients taking Combigan plus additional Lumigan 0.01%
Time frame: Baseline, Month 12
Mean duration of achieving the target IOP with COMBIGAN® alone
Time frame: 12 Months
The percentage of subjects of achieving the target IOP with COMBIGAN® alone during 12 months
Time frame: 12 Months
Definition of patient demographics (descriptive analysis of age and gender)
Define patient demographics in the following patient sub-groups: 1. patients with NTG 2. patients with POAG 3. patients taking Combigan alone 4. patients taking Combigan plus additional Lumigan 0.01%
Time frame: Baseline, Month 12
Ran from Jul 2016 to primary completion in Jul 2018, 24 months.
Of 45 phase 4 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 37. This study's 24 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bimatoprost Ophthalmic Solution